Cogent Biosciences, Inc.
COGT
$39.16
$0.180.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.49% | -25.12% | -27.02% | -32.98% | -36.38% |
| Total Depreciation and Amortization | 12.71% | 18.58% | 12.52% | 21.27% | 8.20% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.56% | -12.16% | 15.82% | 35.21% | 35.08% |
| Change in Net Operating Assets | -61.81% | 37.77% | -21.87% | 1.35% | 33.10% |
| Cash from Operations | -28.56% | -31.78% | -33.09% | -35.26% | -37.65% |
| Capital Expenditure | -0.62% | -57.95% | 40.44% | 79.51% | 81.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.99% | 223.44% | 169.50% | 140.88% | 83.97% |
| Cash from Investing | -16.89% | 222.32% | 168.05% | 139.13% | 83.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14.02% | -88.33% | -90.44% | 29.80% | 29.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 49.97% | 193.10% | 99.07% | 99.07% | -8.41% |
| Cash from Financing | 35.05% | -66.09% | -93.27% | 31.13% | 30.87% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 179.32% | 131.23% | -266.76% | 151.11% | 118.60% |